Deborah Watkins Bruner on Side Effects From Platinum-Based Drugs in Ovarian Cancer

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Approvals in oncology during April included treatments for breast cancer, colorectal cancer, and more.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

The PRECURSOR intervention appeared feasible/acceptable, suggesting a need for patient-centered conversation in incurable gynecologic cancer treatment.

Oncology nurses can support patients facing financial toxicity by offering guidance on available resources and providing emotional support.